Engineered respiratory syncytial viruses with control of cell-to-cell virus transmission for enhanced safety of live virus vaccines
View/ Open
Date
2020-11-24Author
Oomens, Antonius G. P.
Board of Regents/Oklahoma State University and the A & M Colleges
Metadata
Show full item recordAbstract
Highly antigenic yet safe vaccines against diseases caused by Paramyxoviridae viruses such as respiratory syncytial virus (RSV) are provided. The vaccines comprise attenuated Paramyxoviridae viruses with high antigenicity but which display impaired cell-to-cell transmission as a result of genetic manipulation of the gene encoding the matrix (M) protein. In the viruses, the M protein is absent or mutated to a less active form. Screening or assay systems and methods for evaluating the infectivity of mutant M proteins and for identifying suitable M candidates for live-attenuated vaccine virus and VLP production, are also provided.
Collections
- Patents [208]